Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Ras subfamily Stories

2013-06-12 12:28:38

The Jeffrey Epstein VI Foundation celebrates the 10th anniversary of the Program for Evolutionary Dynamics. NEW YORK, June 12, 2013 /PRNewswire/ -- Ten years ago the Program for Evolutionary Dynamics was founded at Harvard with a $30 million dollar grant from a financier called Jeffrey Epstein. Since then, the Program, under the direction of Martin Nowak, a professor of Mathematics and Biology at Harvard, has changed the way in which evolution is studied and utilized. The Program...

2013-05-15 20:23:18

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix(®) (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new...

2013-04-22 14:18:26

Union with Shc keeps potential troublemaker away from bad company and out of the nucleus A protein which is intimately involved in cancer-promoting cell signaling also keeps a key component of the signaling pathway tied down and inactive, a team led by scientists from The University of Texas MD Anderson Cancer Center reports this week in Nature Structural Molecular Biology. Shc, pronounced "schick," plays a key role in activating signals which lead to cell proliferation (and cancer)...

2013-04-09 20:23:52

The Jeffrey Epstein VI Foundation Backs Pivotal research on the evolution of cancer cells. NEW YORK, April 9, 2013 /PRNewswire/ -- The Jeffrey Epstein VI Foundation, a science foundation based in New York City, has helped finance the first mathematical model of how human cancer cells evolve, and more specifically, how they evolve to become immune to inhibitor drug therapy, a popular alternative to chemotherapy. Cellular resistance to inhibitor drug therapy is still a major...

2013-03-08 12:25:11

Pancreatic Cancer Action Network Urges Members Of Congress To Protect Cancer Research MANHATTAN BEACH, Calif., March 8, 2013 /PRNewswire/ -- The Pancreatic Cancer Action Network is calling attention to the potential affects sequestration will have on medical research, and specifically pancreatic cancer research. The onset of sequestration could lead to significant and harmful cuts to the budget of the National Institutes of Health (NIH) and the National Cancer Institute (NCI), which...

2013-03-05 08:28:09

CALGARY, March 5, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that it has completed patient enrollment in a Phase 2 clinical trial evaluating intravenous administration of REOLYSIN(®) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours (REO 016). This trial is a single arm, single-stage, open-label, Phase 2 study of REOLYSIN given intravenously...

2013-02-05 10:28:21

Surprising result suggests that enhancing these mutations´ impact could offer a new way to treat cancer. A typical cancer cell has thousands of mutations scattered throughout its genome and hundreds of mutated genes. However, only a handful of those genes, known as drivers, are responsible for cancerous traits such as uncontrolled growth. Cancer biologists have largely ignored the other mutations, believing they had little or no impact on cancer progression. But a new study from...

2013-01-31 08:29:57

OSLO, January 31, 2013 /PRNewswire/ -- 18-24 patients will be included in the clinical Phase I/II study. Results from the Phase I part are expected in first half of 2013. Principal investigator and oncologist Svein Dueland states: "It is exciting that we now recruit patients for this study, which originates from collaboration between Oslo University Hospital and Norsk Hydro. Participation in clinical trials is an important part of the treatment we can offer cancer...

2013-01-09 09:49:43

"Although mortality from many cancers has been steadily falling, particularly those of the blood [i.e., leukemias], the more important statistic may be that so many epithelial cancers (carcinomas) and effectively all mesenchymal cancers (sarcomas) remain largely incurable." With these words as preface, Nobel laureate James D. Watson, Ph.D., in a newly published paper that he regards "among my most important work since the double helix," sets forth a novel hypothesis regarding the role of...

2012-12-13 08:26:03

CALGARY, Dec. 13, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC) (NASDAQ: ONCY) today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018). The endpoint examines initial percentage tumour changes between...